Loading...

SEPN SEPTERNA INC Company Mergers 8-K Filing

SPTR

SPN

SEPTERNA INC

(SEPN)

2026 8-K

Financial Results Announcement

Clinical Trial Initiated

Financial Results Report

Phase 1 Results

Investor Conference Notice

Leadership Change

Financial Results Announcement

Board Appointment

Investor Presentation Update

Clinical Trial Announcement

Financial Statements

Financial Results

Investor Meetings

Trial Discontinuation

Investor Conference

CFO Appointment

Financial Results

Incorporation Changes

External Links:

On April 13, 2026, Septerna, Inc. announced the start of a Phase 1 clinical trial for SEP-479, a medication aimed at treating hypoparathyroidism. The company also updated its corporate presentation for investors on the same date.

AI Assistant

SEPTERNA INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.